Abstract
ELEVATED plasma levels of the lipoprotein Lp(a) are associated with increased risk for atherosclerosis and its manifestations, myocardial infarction, stroke and restenosis (for reviews, see refs 1–3). Lp(a) differs from low-density lipoprotein by the addition of the glycoprotein apolipoprotein(a), a homologue of plasminogen that contains many tandemly repeated units which resemble the fourth kringle domain of plasminogen, and single homologues of its kringle-5 and protease domain4. As plasma Lp(a) concentration is strongly influenced by heritable factors and is refractory to most drug and dietary manipulation, the effects of modulating it are difficult to mimic experimentally. In addition, the absence of apolipoprotein(a) from virtually all species other than primates precludes the use of convenient animal models. Here we show that transgenic mice expressing human apolipoprotein(a) are more susceptible than control mice to the development of lipid-staining lesions in the aorta, and that apolipoprotein(a) co-localizes with lipid deposition in the artery walls.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Utermann, G. Science 246, 904–910 (1989).
Scanu, A. M. & Fless, G. M. J. clin. Invest. 85, 1709–1715 (1990).
Scanu, A. M., Lawn, R. M. & Berg, K. Ann. Intern. Med. 115, 209–218 (1991).
McLean, J. W. et al. Nature 330, 132–137 (1987).
Paigen, B., Ishida, B., Verstuyft, J., Winters, R. & Albee, D. A. Arteriosclerosis 10, 316–323 (1990).
Paigen, B., Mitchell, D., Reue, K., Morrow, A. & Le Boeuf R. Proc. natn. Acad. Sci. U.S.A. 84, 3763–3767 (1987).
Paigen, B., Morrow, A., Holmes, P., Mitchell, D. & Williams, R. Atherosclerosis 68, 231–240 (1987).
Mehrebian, M., Demer, L. & Lusis, A. Arterio. Thromb. 11, 947–954 (1991).
Rubin, E., Krauss, R., Spangler, E., Verstuyft, J. & Clift, S. Nature 353, 265–267 (1991).
Stewart-Phillips, J. L. & Lough, J. Atherosclerosis 90, 211–218 (1991).
Chiesa, G. et al. J. biol. Chem. (in the press).
Yokode, M., Hammer, R., Ishibashi, S., Brown, M. & Goldstein, J. Science 250, 1273–1275 (1990).
Rath, M. et al. Arteriosclerosis 9, 579–592 (1989).
Cushing, G. L. et al. Arteriosclerosis 9, 593–603 (1989).
Niendorf, A. et al. Virchows Archiv. A. Path. Anat. 417, 105–111 (1990).
Smith, E. B. Atherosclerosis 84, 173–181 (1990).
Pepin, J. M., O'Neil, J. A. & Hoff, H. F. J. Lipid Res. 32, 317–327 (1991).
Harpel, P. C., Gordon, B. R. & Parker, T. S. Proc. natn. Acad. Sci. U.S.A. 86, 3847–3851 (1989).
Hajjar, K. A., Gavish, D., Breslow, J. L. & Nachman, R. L. Nature 339, 303–305 (1989).
Miles, L. A., Fless, G. M., Levin, E. G., Scanu, A. M. & Plow, E. F. Nature 339, 301–303 (1989).
Salonen, E., Jauhianen, L., Zardi, A., Vaheri, A. & Enholm, C. EMBO J. 8, 4035–4040 (1989).
Zioncheck, T. F., Powell, L. M., Rice, G. C., Eaton, D. L. & Lawn, R. M. J. clin. Invest. 87, 767–771 (1991).
McConathy, W. J. et al. FASEB J. 4, A1019 (1990).
Bihari-Varga, M., Gruber, E., Rotheneder, M., Zechner, R. & Kostner, G. M. Arteriosclerosis 8, 851–857 (1988).
Trieu, V. N., Zioncheck, T. F., Lawn, R. M. & McConathy, W. J. J. biol. Chem. 9, 5480–5485 (1991).
Edelberg, J. M., Gonzalez-Gronow, M. & Pizzoo, S. V. Thromb. Res. 57, 155–162 (1990).
Loscalzo, J., Weinfeld, M., Fless, G. M. & Scanu, A. M. Arteriosclerosis 10, 240–245 (1990).
Rouy, D., Grailha, P., Nigon, F., Chapman, J. & Angles-Cano, E. Arteriosclerosis Thromb. 11, 629–638 (1991).
Kojima, S., Harpel, P. C. & Rifkin, D. B. J. Cell Biol. 113, 1439–1445 (1991).
Koschinsky, M. L. et al. Biochemistry 30, 5044–5051 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lawn, R., Wade, D., Hammer, R. et al. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature 360, 670–672 (1992). https://doi.org/10.1038/360670a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/360670a0
This article is cited by
-
Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction
Heart and Vessels (2016)
-
Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis
Cardiovascular Drugs and Therapy (2016)
-
Thrombophilic state in young patients with acute myocardial infarction
Journal of Thrombosis and Thrombolysis (2015)
-
Inhibition of Neointima Formation through DNA Vaccination for Apolipoprotein(a): A New Therapeutic Strategy for Lipoprotein(a)
Scientific Reports (2013)
-
Lipoprotein(a): Reloaded
Current Cardiovascular Risk Reports (2012)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.